A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs
Open Access
- 12 May 2022
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
Abstract
Drug repositioning and the relevance of orphan drug designation for β-thalassemia is reviewed. Drug repositioning and similar terms ('drug repurposing', 'drug reprofiling', 'drug redirecting', ‘drug rescue’, ‘drug re-tasking’ and/or 'drug rediscovery') have gained great attention, especially in the field or rare diseases (RDs), and represent relevant novel drug development strategies to be considered together with the “off-label” use of pharmaceutical products under clinical trial regimen. The most significant advantage of drug repositioning over traditional drug development is that the repositioned drug has already passed a significant number of short- and long-term toxicity tests, as well as it has already undergone pharmacokinetic and pharmacodynamic (PK/PD) studies. The established safety of repositioned drugs is known to significantly reduce the probability of project failure. Furthermore, development of repurposed drugs can shorten much of the time needed to bring a drug to market. Finally, patent filing of repurposed drugs is expected to catch the attention of pharmaceutical industries interested in the development of therapeutic protocols for RDs. Repurposed molecules that could be proposed as potential drugs for β-thalassemia, will be reported, with some of the most solid examples, including sirolimus (rapamycin) that recently has been tested in a pilot clinical trial.This publication has 63 references indexed in Scilit:
- Resveratrol: Antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patientsInternational Journal of Molecular Medicine, 2012
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisThe New England Journal of Medicine, 2011
- The problems with today's pharmaceutical business—an outsider's viewNature Biotechnology, 2011
- Beta-thalassemiaOrphanet Journal of Rare Diseases, 2010
- New uses for old drugsNature, 2007
- Effects of rapamycin on accumulation of α‐, β‐ and γ‐globin mRNAs in erythroid precursor cells from β‐thalassaemia patientsEuropean Journal of Haematology, 2006
- Thalidomide as a novel therapeutic agent: new uses for an old productDrug Discovery Today, 2005
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Rapamycin‐mediated induction of γ‐globin mRNA accumulation in human erythroid cellsBritish Journal of Haematology, 2004
- FinasterideThe New England Journal of Medicine, 1994